Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.

OBJECTIVES The arrhythmogenic and electrophysiologic properties of sotalol, a class III antiarrhythmic drug, administered alone and in combination with mexiletine, a class I antiarrhythmic drug, were compared in conscious dogs predisposed to torsade de pointes arrhythmias. BACKGROUND The utility of sotalol is limited by proarrhythmia related to excessive delays in repolarization. The addition of mexiletine may limit the risk of torsade de pointes because it reduced in vitro the sotalol-induced increase in action potential duration. METHODS Two studies were performed in eight hypokalemic dogs (plasma potassium level < or = 3.2 mmol/liter) with chronic atrioventricular block (mean ventricular cycle length, RR 1,100 ms) at 3-day intervals using a crossover protocol. Intravenous sotalol (4.5 + 1.5 mg/kg body weight per h) alone was given for 2 h, or, on another day, an intravenous mexiletine infusion (4.5 + 1.5 mg/kg per h) was begun 30 min before sotalol infusion. Spontaneous ventricular cycle length and QT interval and ventricular effective refractory period at the 1,000-ms pacing cycle length were measured at baseline and 30 min after the onset of each drug infusion. The electrocardiogram (ECG) was continuously monitored for torsade de pointes. RESULTS Sotalol plus mexiletine and sotalol alone had a significant (p < or = 0.05) and similar effect on ventricular cycle length (+ 800 +/- 93 vs. + 690 +/- 104 ms [mean +/- SEM]) and ventricular effective refractory period (+ 20 +/- 4 vs. + 25 +/- 4 ms), but sotalol plus mexiletine had a lesser effect on QT interval (+ 20 +/- 6 vs. + 50 +/- 8 ms, p < or = 0.05). Torsade de pointes is less frequent (one of eight dogs vs. six of eight dogs, p = 0.02) with sotalol plus mexiletine than with sotalol alone. CONCLUSIONS The coadministration of a class Ib agent can reduce the proarrhythmic potential of a class III drug in experimental animals predisposed to torsade de pointes arrhythmias and further suggests the clinical utility of such a strategy.

[1]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[2]  U. Borchard,et al.  Electrophysiological characterization of the class III activity of sotalol and its enantiomers. New interpretation of use-dependent effects. , 1988, Arzneimittel-Forschung.

[3]  E. Carmeliet Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.

[4]  K. Nademanee,et al.  Sotalol , 1987, Drugs.

[5]  J. Davy,et al.  Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. , 1991, The Journal of pharmacology and experimental therapeutics.

[6]  A. Shah,et al.  Mexiletine for treatment of torsade de pointes. , 1984, American heart journal.

[7]  A. Kadish,et al.  The effect of quinidine and mexiletine on the adaptation of ventricular refractoriness to an increase in rate. , 1991, American heart journal.

[8]  J. Davy,et al.  Methods and limitations of an experimental model of long QT syndrome. , 1991, Journal of pharmacological methods.

[9]  C. January,et al.  A Model for Early Afterdepolarizations: Induction With the Ca2+ Channel Agonist Bay K 8644 , 1988, Circulation research.

[10]  G. Kay,et al.  Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.

[11]  M. Arita,et al.  Comparison of the inhibitory effects of mexiletine and lidocaine on the calcium current of single ventricular cells. , 1986, Life sciences.

[12]  M. Arita,et al.  ELECTROPHYSIOLOGICAL ACTIONS OF MEXILETINE (Kö1173) ON CANINE PURKINJE FIBRES AND VENTRICULAR MUSCLE , 1979, British journal of pharmacology.

[13]  M R Franz,et al.  Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo. , 1989, The Journal of pharmacology and experimental therapeutics.

[14]  K. Nademanee,et al.  Sotalol: a beta blocker with unique antiarrhythmic properties. , 1987, American heart journal.

[15]  J. Brachmann,et al.  Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. , 1991, The American journal of cardiology.

[16]  A. Keren,et al.  Etiology, Warning Signs and Therapy of Torsade de Pointes: A Study of 10 Patients , 1981, Circulation.

[17]  D. Wyse,et al.  Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans. , 1987, Journal of the American College of Cardiology.

[18]  A. Varró,et al.  Sotalol and Mexiletine: Combination of Rate‐Dependent Electrophysiological Effects , 1990, Journal of cardiovascular pharmacology.

[19]  N. Akaike,et al.  Blockage of the sodium current in isolated single cells from rat ventricle with mexiletine and disopyramide. , 1985, Journal of molecular and cellular cardiology.

[20]  J. Barlow,et al.  Sotalol, hypokalaemia, syncope, and torsade de pointes. , 1984, British heart journal.

[21]  B. Surawicz,et al.  Effect of Antiarrhythmic Drugs on the Cycle Length-Dependent Action Potential Duration in Dog Purkinje and Ventricular Muscle Fibers , 1986, Journal of cardiovascular pharmacology.

[22]  A. Mallet,et al.  Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. , 1991, Circulation.

[23]  B. Strasberg,et al.  Polymorphous ventricular tachycardia: clinical features and treatment. , 1979, The American journal of cardiology.

[24]  W Craelius,et al.  QTU Prolongation and Polymorphic Ventricular Tachyarrhythmias Due to Bradycardia‐Dependent Early: Afterdepolarizations Afterdepolarizations and Ventricular Arrhythmias , 1988, Circulation research.

[25]  D. Roden,et al.  Mexiletine in the Treatment of Resistant Ventricular Arrhythmias: Enhancement of Efficacy and Reduction of Dose‐related Side Effects by Combination with Quinidine , 1983, Circulation.

[26]  S. Hering,et al.  Sodium current in freshly isolated and in cultured single rat myocardial cells: frequency and voltage-dependent block by mexiletine. , 1983, Journal of molecular and cellular cardiology.

[27]  S. Nattel,et al.  Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. , 1989, Journal of the American College of Cardiology.

[28]  B. Singh,et al.  A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 , 1970, British journal of pharmacology.

[29]  J. Bigger,et al.  Electrophysiological and Beta‐Receptor Blocking Effects of MJ 1999 on Dog and Rabbit Cardiac Tissue , 1970, Circulation research.

[30]  A. Uprichard,et al.  Atenolol, but not mexiletine, protects against stimulus‐induced ventricular tachycardia in a chronic canine model , 1989, British journal of pharmacology.

[31]  B. Lüderitz,et al.  Combination of Antiarrhythmic Drugs , 1991, Journal of cardiovascular pharmacology.

[32]  A. Varró,et al.  The combined electrophysiological effects of lignocaine and sotalol in canine isolated cardiac Purkinje fibres are rate‐dependent , 1990, British journal of pharmacology.

[33]  G. Cheymol,et al.  Rapid and sensitive column liquid chromatographic determination of sotalol in plasma. , 1989, Journal of chromatography.